



Omni Scottsdale Resort & Spa at Montelucia
Scottsdale, AZ

V14 3.25.25 * subject to change

Sunday May 4					
3:00 PM	7:00 PM	Registration Open	Alhambra Foyer		
3:00 PM	7:00 PM	Exhibit and Poster Setup	Alhambra Ballroom B		
6:30 PM	8:00 PM	Welcome Reception - (Hors-d'oeurves, dinner on your own)	Oasis Pool Bar		
Monday May 5					
7:00 AM	6:00 PM	Registration Open	Alhambra Foyer		
7:00 AM	9:00 AM	Exhibit and Poster Setup	Alhambra Ballroom B		
7:00 AM	7:30 AM	Breakfast	Alhambra Terrace		

Day 2 | Innovations in Transfusion Medicine and Cellular Therapeutics: Enhancing Outcomes in Trauma and Critical Care

Talks will focus on the intersection of transfusion medicine and regenerative medicine, highlighting advancements in blood-derived therapeutics, cellular therapies, and innovative regenerative products for treating acute and chronic conditions linked to trauma and critical illness. Attendees will gain valuable insights into how these innovations can significantly improve patient outcomes.

7:30 AM 7:35 AM **Welcome & Introductions**

Shibani Pati MD PhD

CTTACC Conference Chair; Director Center for Research in Transfusion Med and Cell Therapies; Vice Chair and Professor, UCSF

Session 1 | Topics in Trauma and Transfusion Medicine

Moderators:	Ernest "Gene" Moore MD FACS, Distinguished Professor of Surgery, Ernest E Moore Shock Trauma Center at Denver Health					
	Susan Rowell MD, Professor of Surgery, Trauma and Acute Care Surgery, Director, Surgical Critical Care Fellowship Program, Co-Director, Adult Surgical Intensive Care Unit					
7:35 AM	7:55 AM	Injury Mechanisms and Characteristics, Implications for Future Clinical Trial Planning				
		Jason Sperry MD MPH FACS				
		Section Chief, Trauma Surgery: Professor of Surgery and Critical Care; Director of Acute Care Surgery Fellowship, University of Pittsburgh				
7:55 AM	8:15 AM	Cold Stored Platelets for Transfusion in Hemorrhagic Shock and TBI				
		Matthew Neal MD FACS				
		Watson Chair and Professor of Surgery, Director of Emergency General Surgery, Co-Director, Pittsburgh Trauma and Transfusion Medicine Research Center, Professor of Clinical and Translational Science and Critical Care Medicine, University of Pittsburgh				
8:15 AM	8:35 AM	Donor and Recipient Safety and Transfusion Efficacy Research: Past, Present and Future				
		Michael Busch MD PhD				
		Director Emeritus & VP, Vitalant; Professor, Department of Laboratory Medicine, UCSF				
8:35 AM	9:00 AM	Avoiding Iatrogenic Resuscitation Injury after Traumatic Brain Injury: Repairing the Blood Brain Barrier John Holcomb MD FACS				
		COL, USA (Ret); Professor of Surgery, Department of Surgery, University of Alabama at Birmingham				
9:00 AM	9:20 AM	Making your Hemorrhage Control Intervention Trial a Success: Key				
		Areas to Consider				
		Jan Jansen MD Professor, General Surgery Trauma Section, University of Alabama at				
		Birmingham				
9:20 AM	9:40 AM	Cell Mediated Fibrinolysis: A Bridge to Organ Regeneration After Ischemia Reperfusion Injury				

Hunter Moore MD PhD

Surgical Director of Kidney Transplant and Living Donor, AdventHealth

Transplant Institution at Porter

9:40 AM 9:55 AM Question & Answer Panel | Session 1 9:55 AM 10:15 AM **Break & Exhibits** Alhambra Ballroom B Session 2 | Cellular Therapies in Acute and Chronic Illness Moderators: Clifford Lowell MD PhD, Distinguished Professor, Chair of Department of Laboratory Medicine, UCSF Michael Matthay MD, Professor of Pulmonary Critical Care Medicine; Research Lab Director, Acute Lung Injury and ARDS: Research and Clinical Trials; Critical Care Specialist, UCSF 10:15 AM 10:35 AM Cellular Reprograming in Human Disease Deepak Srivastava MD President & Senior Investigator, Gladstone Institutes; Professor, Departments of Pediatrics & Biochemistry & Physics, Gladstone Institute/UCSF 10:35 AM 10:55 AM Repairing the Infarcted Heart **Chuck Murry MD PhD** Chair and Professor, Department of Stem Cell Biology & Regenerative Medicine; Director, Eli and Edyth Broad Center for Regenerative Medicine & Stem Cell Research, Keck School of Medicine of USC 10:55 AM 11:15 AM In Utero Stem Cell Therapy Spina Bifida, From the Barn to the Bedside Diana L Farmer MD FACS FRCS Chair and Distinguished Professor, Department of Surgery, Chief of Pediatric Surgery, Shriner's Hospitals for Children; Founder and Co-director, Center for Surgical Bioengineering, UC Davis 11:15 AM 11:35 AM Lessons Learned from Clinical Trials in Cell Therapy for TBI Charles S Cox Jr MD FACS The George and Cynthia Mitchell Distinguished Chair in Neurosciences; Director, Children's Program in Regenerative Medicine; Professor, Department of Pediatric Surgery, UTHealth Houston 11:35 AM 11:50 AM Question & Answer Panel | Session 2 11:50 AM 12:50 PM Valencia Lawn Session 3 | Blood Derived Therapeutics as a Discovery Platform of Novel Regenerative Factors Moderators: Cédric Ghevaert MD PhD FRCP FRCPath, Professor of Transfusion Medicine, Department of Haematology, University of Cambridge Anirban Sen Gupta PhD, Wallace R. Persons Professor of Engineering, Department of Biomedical Engineering, Case Western University 1:10 PM 12:50 PM Blood-based Approaches to Rejuvenate the Aging Brain Saul Villeda PhD Associate Professor, Department of Anatomy; Associate Director, Bakar Aging Research Institute, UCSF 1:10 PM 1:30 PM Rescuing Regeneration in Aging Muscle by Manipulating Blood-Borne **Factors Amy Wagers PhD** Chair and Forst Family Professor, Department of Stem Cell and Regenerative Biology; Executive Committee Member, Harvard Stem Cell Institute 1:30 PM 1:50 PM Translating Platelet Rich Plasma Research to Clinical Use in Orthopedics **Anthony Luke MD MPH** Professor, Department of Orthopaedic Surgery; Director, Human Performance Center, UCSF 1:50 PM 2:10 PM Freeze-Dried Platelet Derived Hemostatic Agent in Severe Surgical Bleeding: Results of a Pilot Randomized Clinical Trial Jakob Stensballe MD PhD Board Member, The Medical Society of Copenhagen (DMSK); Senior Consultant, Department of Anesthesiology and Centre for Head & Orthopedics, Rigshospitalet, Copenhagen 2:10 PM 2:25 PM Question & Answer | Session 3 2:25 PM 2:45 PM **Break & Exhibits** Alhambra Ballroom B

Session 4 | Emerging Concepts and Innovative Therapeutics in Critical Care

Moderators: Matthew Neal MD FACS, Watson Chair and Professor of Surgery, Director of Emergency General Surgery, Co-Director, Pittsburgh Trauma and Transfusion Medicine Research Center, Professor of Clinical and Translational Science and Critical Care Medicine, University of Pittsburgh

	•	and MD MPH FACS, Clinical Assistant Professor, Surgery, University of Arizona t of Surgery Division of Trauma, Surgical Critical Care, Burns and Acute Care Surgery	
2:45 PM	3:05 PM	The Immunobiology of ARDS	
		Clifford Lowell MD PhD	
		Distinguished Professor and Chair of Department of Laboratory Medicine, UCSF	
3:05 PM	3:25 PM	Engineering stem cell derived extracellular vesicles and lipid nanoparticles for targeted delivery Aijun Wang MD PhD Professor and Vice Chair, Departments of Surgery and Biomedical	
		Engineering; Co-director, Center for Surgical Bioengineering, UC Davis	
3:25 PM	3:45 PM	MSCs and Bacterial Pneumonia in Mice: Replicating ARDS Phe Patients Michael Matthay MD Professor of Pulmonary Critical Care Medicine; Research Lab Director, Acut Lung Injury and ARDS: Research and Clinical Trials; Critical Care Specialist	re
3:45 PM	4:05 PM	UCSF Single cell multi-omics reveals outcome based circulating leu populations in human trauma Timothy R Billiar MD	kocyte cell
		Distinguished Professor and Chair, Department of Surgery; Associate Senic Vice Chancellor for Clinical Academics, University of Pittsburgh; Executive Vice President and Chief Scientific Officer, UPMC	or
4:05 PM	4:25 PM	Early Alterations in Innate Immunity and Role in Chronic Crit Joseph Cuschieri MD Professor of Surgery and Lab Medicine, Chief of Surgery at Zuckerberg Sa Francisco General Hospital and Trauma Center; Trauma Medical Director,	
4:25 PM	4:45 PM	Preclinical drug development for ischemic states using large models Emin Maltepe MD PhD Professor, Department of Pediatrics and Neonatology, UCSF	animal
4:45 PM	5:05 PM	Fibrinolysis in Clinical Translation: New Therapeutic Opportu Surgical Pleural Space Diseases in Trauma and Beyond Christopher Barrett MD	nities in
		Assistant Professor, UNMC Department of Surgery, Division of Acute Care Surgery; Surgeon, Nebraska Medicine	
5:05 PM	5:20 PM	Question & Answer Session 4	
5:20 PM	6:15 PM	Poster Session	Alhambra Ballroom B
	Cod	ordinator: Elena Nedelcu MD	
		Professor Lab Medicine UCSF	
6:15 PM	7:00 PM	Reception	Kasbah Patio
7:00 PM	9:00 PM	Dinner & Awards Ceremony	Cojito Plaza
Tuesda	y May 6		
7:00 AM	6:00 PM	Registration Open	Alhambra Foyer
7:00 AM	7:30 AM	Breakfast	Alhambra Terrace
D-1/2 I	Neval Dise	d Draducta Stom Call Darivad Bland Military Haalth Soci	-1

Day 3 | Novel Blood Products, Stem Cell Derived Blood, Military Health Session

Talk topics will delve into stem cell-derived blood components and innovative blood products aimed at providing new therapies for trauma and critical care patients. We'll explore recent findings related to plasma-based treatments for conditions such as sepsis, traumatic brain injury, and burns. Additionally, we'll address the regulatory challenges faced in approving these novel products. The day will wrap up with a session on military health, concentrating on optimizing care and identifying gaps in research and the treatment of injured warfighters on the battlefield/pre-Role 2 care. Three main areas of interest will be discussed: 1) management of hemorrhage on the battlefield with novel blood products and therapeutics, 2) management of organ failure on the battlefield, and 3) management of TBI and SCI on the battlefield. A fourth topic on wound management and infection will be covered in a focus group discussion on May 7th.

Session 5 | Stem Cell Derived Blood Components and Novel Blood Products

Moderators: Jessica Cardenas PhD, Associate Professor, Department of Surgery, CU Anschutz

Lucy Kornblith MD FACS, Associate Professor UCSF Department of Surgery and Lab Medicine, Director of Research ZSFGH

	8:10 AM	Cédric Ghevaert MD PhD FRCP FRCPath
	8:10 AM	
	8:10 AM	Professor of Transfusion Medicine, Department of Haematology, University of Cambridge
		Developing a Whole Blood Substitute - The Inner Workings of the On
		Demand Blood Program
		Vincent B Ho MD MBA Chair and Professor, Department of Radiology and Bioengineering, Director,
		4D Bio3 Center for Biotechnology, Uniformed Services University of the Health Sciences
8:10 AM	8:30 AM	Platelet-inspired Synthetic Nanomedicine for Targeted Hemostatic
		Applications Anirban Sen Gupta PhD
		Wallace R. Persons Professor of Engineering, Department of Biomedical Engineering, Case Western University
8:30 AM	8:50 AM	The Hidden Components: Extracellular Vesicles and Mitochondrial DNA
		in Blood Products
		Philip Norris MD
		Director of Laboratory Science and VP of Research and Scientific Programs, Vitalant; Professor, Department of Laboratory Medicine, UCSF
8:50 AM	9:10 AM	Translational Applications of Platelet Lysates and Extracellular Vesicles:
		Why, What, and How
		Thierry Burnouf PhD Distinguished Professor and Vice Dean, Graduate Institute of Biomedical
		Materials and Tissue Engineering, Taipei Medical University
9:10 AM	9:30 AM	Gene-edited iPSC Derived RBCs for Large Scale Production
		Kyle Cromer PhD Assistant Professor, UCSF Department of Surgery
9:30 AM	9:45 AM	Ouestion & Answer Session 5
9:45 AM	10:05 AM	Break & Exhibits Alhambra Ballroom B
		herapeutics in Trauma, Burns, Sepsis
		chreiber MD FACS FCCM, COL, MC, USAR, Adjunct Professor of Surgery, USUHS
	Joseph Ra	ppold MD, CAPT (Ret) US Navy, Medical Director, Cellphire, Inc
10:05 AM	10:25 AM	Plasma constituents in regulating post-injury coagulopathy, endothelial homeostasis, and organ injury
		Jessica Cardenas PhD
		Associate Professor, Department of Surgery, CU Anschutz
10:25 AM	10:45 AM	Defining the Endotheliopathy and Epitheliopathy of Trauma and the Impact of Blood Product Resuscitation
		Shibani Pati MD PhD
		CTTACC Conference Chair; Director Center for Research in Transfusion Med and Cell Therapies; Vice Chair and Professor, UCSF
10:45 AM	11:05 AM	Endotheliopathy, Fibrinolysis, and Plasma Resuscitation in Burn Shock Jeff Shupp MD
		Professor of Surgery, Plastic Surgery, Biochemistry, Cellular & Molecular Biology, Georgetown University
	11:25 AM	Plasma in Septic Shock; Results of a Randomized Clinical Pilot Trial Jakob Stensballe MD PhD
11:05 AM		Board Member, The Medical Society of Copenhagen (DMSK); Senior
11:05 AM		,
11:05 AM		Consultant, Department of Anesthesiology and Centre for Head &
	11:40 AM	
11:25 AM	11:40 AM 12:05 PM	Consultant, Department of Anesthesiology and Centre for Head & Orthopedics, Rigshospitalet, Copenhagen Question & Answer Session 6 Special Lecture Acellular Tissue Engineered Vessels: Civilian and
11:25 AM		Consultant, Department of Anesthesiology and Centre for Head & Orthopedics, Rigshospitalet, Copenhagen Question & Answer Session 6
11:25 AM		Consultant, Department of Anesthesiology and Centre for Head & Orthopedics, Rigshospitalet, Copenhagen Question & Answer Session 6 Special Lecture Acellular Tissue Engineered Vessels: Civilian and Military Experience
11:25 AM		Consultant, Department of Anesthesiology and Centre for Head & Orthopedics, Rigshospitalet, Copenhagen Question & Answer Session 6 Special Lecture Acellular Tissue Engineered Vessels: Civilian and Military Experience Introduction: Martin A Schreiber MD FACS FCCM

1:05 PM	1:20 PM	Special Lecture AFIRM Anthony Atala MD
		Professor and Chair of Urology, Wake Forrest
Session 7	' Military F	lealth Session Focused on Battlefield Strate

1:55 PM

tlefield Strategies for Care

Moderators:	Jeremy Cannon MD FACS, Col USAF (Ret), Professor of Surgery, University of Pennsylvania			
		Gurney MD FACS, Chief, Joint Trauma System, COL MC USA; US Army Institute of search, Fort Sam Houston		
1:20 PM	1:35 PM	Distinguished Presentation		
		Stephen Ferrara MD CAPT USN (Ret), Acting Assistant Secretary of Defense for Health Affairs		
1:35 PM	1:55 PM	Preparations for Large Scale Combat Operations: Joint Trauma System Standpoint Jennifer Gurney MD FACS		
		Chief, Joint Trauma System, COL MC USA; US Army Institute of Surgical Research, Fort Sam Houston		

2:15 PM The Combat Casualty Care Peacetime Effect at a Cross Roads: Are we Preparing to Fail or Win? (Civilian Perspective)

Jeremy Cannon MD FACS

Col USAF (Ret), Professor of Surgery, University of Pennsylvania

2:15 PM 2:35 PM **Blood Replacement Strategies in Future Large-Scale Operations Novel Blood Products**

Martin A Schreiber MD FACS FCCM

COL, MC, USAR, Adjunct Professor of Surgery, USUHS

Topic 1 | Management of Hemostasis and Hemorrhagic Shock on the Battlefield/pre-Role 2

Andre Cap	MD PhD, Travis M Polk MD FACS	
2:50 PM	The Future of Battlefield Hemmorhage Control Travis M Polk MD FACS CAPT USN; Chair, Joint Program Committee-6; Director, Combat Casualty Care Research Program (CCCRP); US Army Medical Research and Development Command (USAMRDC), Defense Health Agency	
3:05 PM	Blood on the Battlefield; When will we Finally get back to WN Andre Cap MD PhD COL USA (Ret); Board Director and Chief Scientific Officer, Velico	WII Capabilities
3:35 PM	Panel Discussion 1). Novel/alternate blood products regulatory approval (dried plasma, dried plate blood derived products, whole blood, oxygen carriers, blood substitutes) 2). Logist Transport of product/patient (containers) 3). Battlefield Regulatory approval Bethany Brown PhD, Mike Fitzpatrick PhD, Jennifer Gurney MD, Martin Schreiber MD, Beth Shaz MD, Ralph Vassallo MD FACP, Carlos Villa MI PhD	tics and
3:50 PM	Break	Alhambra Foyer
6:00 PM	Exhibitor and Poster Takedown	Alhambra Ballroom B
	2:50 PM 3:05 PM 3:35 PM	Travis M Polk MD FACS CAPT USN; Chair, Joint Program Committee-6; Director, Combat Casualty Care Research Program (CCCRP); US Army Medical Research and Development Command (USAMRDC), Defense Health Agency 3:05 PM Blood on the Battlefield; When will we Finally get back to WA Andre Cap MD PhD COL USA (Ret); Board Director and Chief Scientific Officer, Velico 3:35 PM Panel Discussion 1). Novel/alternate blood products regulatory approval (dried plasma, dried plate blood derived products, whole blood, oxygen carriers, blood substitutes) 2). Logist Transport of product/patient (containers) 3). Battlefield Regulatory approval Bethany Brown PhD, Mike Fitzpatrick PhD, Jennifer Gurney MD, Martin Schreiber MD, Beth Shaz MD, Ralph Vassallo MD FACP, Carlos Villa Mi PhD 3:50 PM Break

Topic 2 | Management of Traumatic Brain Injury and Spinal Cord Injury on the Battlefield/pre-Role 2

Moderator:	Geoffrey	Ling MD PhD
3:50 PM	4:05 PM	Innovative Approaches to Manage TBI on the Battlefield and in Remote Settings
		Geoffrey Ling MD PhD
		COL USA (Ret) Professor of Neurolgy USUHS, Professor of Neurology, Johns H
4:05 PM	4:20 PM	TBI Care in Prehospital, Combat and Austere Environments: New Brain Trauma Foundation Guidelines GJ Hawryluk MD, PhD
		Neurosurgeon, Cleveland Clinic; Adjunct Associate Professor of Neurosurgery, Uniformed Services University; Medical Director and Scientific Advisory Board Chair, Uniformed Services University
4:20 PM	4:50 PM	Panel Discussion

1). Novel blood products and resuscitation (plasma for TBI...., dried platelets...) 2). Point of Care Devices- Biomarkers for TBI and SCI evaluation, ICP monitoring, MOBI? 3). Cell Therapies/Regenerative interventions 4). Logistics and Transport for TBI and SCI

Charles S Cox Jr MD FACS, James Guest MD PhD, GJ Hawryluk MD PhD, Jan Jansen MD, Susan Rowell MD, Jason Sperry MD, Dallas Hack MD

Topic 3 | Management of Organ Failure and Sepsis

Moderator:	Kevin Chu	ng MD	
4:50 PM	5:05 PM	Long Term Organ Support in a Wartime Setting Kevin Chung MD	
		COL USA (Ret), CMO Seastar Medical	
5:05 PM	5:20 PM	Renal Replacement Therapy in Large Scale Combat Operations Ian Stewart MD	S
		Col, USAF, MC, Vice chair for Clinical Research, Professor of Medicine, Uniformed Services University	
5:20 PM	5:35 PM	Autologous vs Allogeneic Mesenchymal Stromal Cells for ARD Multiorgan Failure Managment: Present and Future Applicatio	
		Andriy Batchinsky MD	
		Professor of Surgery & Medicine, USU, Geneva Foundation, AREVA	
5:35 PM	6:05 PM	Panel Discussion 1). Novel blood products and resuscitation- dried plasma/ platelets. 2). Cellular The Device for group failure supports mobile dialysis. ECMO. 4). Legistics Transports	erapies 3).
		Devices for organ failure support: mobile dialysis, ECMO. 4). Logistics Transport Andriy Batchinsky MD, Kenton Gregory MD, Ernest "Gene" Moore MD FACS, Jakob Stenseballe MD PhD, Ian Stewart MD	
Summary o	f Thought	s and Military Health Session- Future Research Directions of DO	D
6:05 PM	6:20 PM	-	_
0.05 FM	0.20 FM	Thoughts on Future Directions	
		Lester Martinez-Lopez MD MG USA (Ret) Former Assistant Secretary of Defense for Health Affairs (ASDHA)	
6:20 PM	6:30 PM	Wrap Up	
		Jennifer Gurney MD FACS	
		Chief, Joint Trauma System, COL MC USA; US Army Institute of Surgical Research, Fort Sam Houston	
		Jeremy Cannon MD FACS	
		Col USAF (Ret), Professor of Surgery, University of Pennsylvania	
6:30 PM	7:15 PM	Reception	Valencia Lawn
7:15 PM	7:35 PM	2025 Keynote Transforming Battlefield Trauma Care	
		Introduction: Joseph Rappold MD FACs Capt (USN Ret)	
		Frank Butler MD FAAO FUHM	
		CAPT Medical Corps USN (Ret) Consultant in Tactical Combat Casualty Car Joint Trauma System, Adjunct Professor of Military and Emergency Medicine Uniformed Services University, Presidential Citizens Medal Recipient 2024	
7:35 PM	9:30 PM	Dinner	Valencia Lawn
Wednesda	v May 7		
7:00 AM	3:00 PM	Registration Open	Alhambra Foyer
7:00 AM	8:00 AM	Exhibitor and Poster Takedown	Alhambra Ballroom B
7:00 AM	7:30 AM	Breakfast	Alhambra Terrace

Day 4 | Cell and Gene Editing of Stem Cell and Blood Products, Wound Healing and Dried Plasma Focus Group

Talks will focus on exciting advancements in cell and gene editing, as well as the potential for scaling up the production of enhanced, personalized blood and cell therapies for trauma and critical care patients outside of oncological applications. We will also discuss novel topics in blood and blood products. We will host a special lecture on integrative practices in chronic critical illness followed by a session on innovative solutions in wound healing and infection control. The day will conclude with a focus group on the state of the science and challenges in the production of a dried plasma product.

Session 8 | Advancing the Field of Cell and Gene Editing

Moderators: Fabio Triolo, DdR, MPhil, PhD, The Clare A. Glassell Distinguished Chair, Director, Cellular

Therapy Core, Professor, Program in Regenerative Medicine

Beth Shaz MD, Professor and Deputy Director of Marcus Center for Cellular Cures, Duke University

7:30 AM	7:50 AM	Manufacturing Cell and Gene Therapies in the Academic Setting Brian Shy MD PhD
		Assistant Professor, Department of Laboratory Medicine, Director, Human Islet and Cellular Transplantation GMP Facility, UCSF
7:50 AM	8:10 AM	Improving on Nature: Interface Re-engineering of Ligand-based CAR T
		Cells for Enhanced Efficacy
		Arun Wiita MD PhD
		Professor, Department of Laboratory Medicine; Assistant Director, Clinical Cytogenics Laboratory, UCSF
8:10 AM	8:30 AM	Non-Genetic Modification of Blood and Somatic Cells Scale Brett Janis PhD
		CEO/CSO, Treasurer and Co-founder, DesiCorp Inc.
8:30 AM	8:50 AM	Leveraging the Platelet Transcriptome to Decipher Platelet Function and Dysfunction: In Circulation and In Storage Lucy Kornblith MD FACS
		Associate Professor UCSF Department of Surgery and Lab Medicine, Director of Research ZSFGH
8:50 AM	9:10 AM	Regulatory Science and Navigating the FDA Regulatory Landscape
		Steven R Bauer PhD
		Chief Regulatory Science Affairs Program, Wake Forest Institute for Regenerative Medicine (WFIRM), Former FDA Chief of Cellular and Tissue Therapy Branch, Division of Cellular and Gene Therapies CBER
Advancing	Blood The	rapeutics Insights into Potency and Informative Assays
9:10 AM	9:30 AM	Extracellular Mitochondria and TBI-induced Endotheliopathy
		Jing Fei Dong MD PhD
		Bloodworks Northwest, Professor of Medicine University of Washington
9:30 AM	9:50 AM	Defining Oxygen Transport Potency for RBCs and Bio-synthetic Alternatives
		Allan Doctor MD
0.50.444	10.10.11	Professor University of Maryland Department of Pediatrics
9:50 AM	10:10 AM	Informative Assays to Guide Clinical Development of Novel Blood
		Products
		Larry Corash MD
10.10.44	10.25 444	Senior Vice President and Chief Scientific Officer, Cerus Corporation
10:10 AM	10:25 AM	Question & Answer Panel Session 8
10:25 AM	10:40 AM	Break Alhambra Foyer
10:40 AM	11:00 AM	Special Lecture Integrative Medicine: Fundamental Practices to enhance outcomes in Chronic Critical Illness Sangeeta Pati MD FACOG ABOIM
		Founder Take My Power Back Initiative, Founder & Medical Director, SaJune Institute for Restorative and Regenerative Medicine, Medical Director GlowSpring Health, Founder and CEO MDPrescriptives
Session 9	Next-Gene	eration Solutions for Wound Healing, Infection Control, and Tissue
Regeneration		, and a sound soun
	Geoffrey G Biomedical E	Furtner MD FACS, Chair Department of Surgery; Professor Surgery; Professor Engineering, University of Arizona College of Medicine er MD , COL USA (Ret)
11:00 AM	11:20 AM	A Systems Approach to Austere Total Wound Management
		Stuart Tyner MD, COL USA (Ret)
11:20 AM	11:40 AM	Novel Cellular Therapeutics in Wound Healing Geoffrey Gurtner MD FACS
		Chair Department of Surgery; Professor Surgery; Professor Biomedical Engineering, University of Arizona College of Medicine
11:40 AM	12:30 PM	Industry Quick Shot Talks
12:30 PM	1:30 PM	Lunch Alhambra Foyer
		oup: From Battlefield to Bedside: Overcoming Challenges in Developing

Session 10 | Focus Group: From Battlefield to Bedside: Overcoming Challenges in Developing a Dried Plasma Product for Military and Civilian Use

The goal of this focus group is to facilitate collaborative discussions and achieve consensus on key issues, including: 1) Identifying challenges and barriers in the development, licensing, production, distribution, and implementation of dried plasma products; 2) Clarifying the medical need and potential applications of dried plasma beyond pre-hospital and trauma settings; 3) Proposing solutions or strategies to address these challenges and barriers; and 4) Developing consensus statements/publication(s) addressing these topics. The panel will be primarily responsible for addressing discussion topics and will prepare potential consensus publications.

	Session Ch	nair/Moderator:	Anthony	Pusateri PhD
--	------------	-----------------	---------	--------------

Chief Scientist, Leidos and Naval Medical Research Unit

Co-Chair/Moderator: Isabel Lauren Jackson PhD

Founding Principal, True North BioPharma, LLC

1:30 PM 1:45 PM Dried Plasma Background and Focus Group Introduction

Anthony Pusateri PhD

Chief Scientist, Leidos and Naval Medical Research Unit

1:45 PM 2:00 PM Prehospital Transfusion Experience and How Could Dried Plasma Be

Beneficial?

Jason Sperry MD MPH FACS

Section Chief, Trauma Surgery: Professor of Surgery and Critical Care; Director of Acute Care Surgery Fellowship, University of Pittsburgh

2:15 PM Pharmacy and Billing Alternatives for Dried Plasma

Michael Ganio PharmD MS

Senior Director, Pharmacy Practice and Quality, ASHP

Topic: Potential Non-trauma and In-hospital Uses for Dried Plasma – An Anesthesiologist's Perspective

Roman Dudaryk MD

Ryder Trauma Center/University of Miami Professor of Anesthesiology, Director of Quality

2:30 PM 4:00 PM Panel Discussion

2:30 PM

2:00 PM

2:15 PM

Panelists

Bethany Brown PhD, American Red Cross; Lisa Buckley MPH, Velico Medical, Andre P. Cap MD PhD, Velico Medical; Laurence M. Corash MD, Cerus Corporation; Roman Dudaryk MD, University of Miami; G. Michael Fitzpatrick PhD, Cellphire Therapeutics; Michael Ganio PharmD MS, American Society of Hospital Pharmacists; Adam Gerber MD PhD, Octapharma; Richard Gonzales MS, US Army Medical Materiel Development Activity; Jennifer M. Gurney MD, Department of Defense; Isabel L. Jackson PhD, True North Biopharma; Lester Martinez-Lopez MD MPH, Department of Defense; Ernest "Gene" Moore MD, University of Colorado; Hunter B Moore MD, Advent Health; Vijay Nair PhD, Octapharma; Shibani Pati MD PhD, University of California San Francisco; Michael A Policastro MD, Mercy Health; Travis Polk MD, Department of Defense; Anthony E. Pusateri PhD, 59th Medical Wing; Joseph F. Rappold MD, Cellphire Therapeutics; Jeffrey W. Shupp MD, Medstar Washington Hospital Center; Toby Silverman MD, Biomedical Advanced Research and Development Authority; Jason L. Sperry MD MPH, University of Pittsburgh; Ralph Vassallo MD, Vitalant; Carlos Villa PhD, FDA

Discussion Points

The primary focus of this discussion will be on civilian applications, with some crossover into military and disaster-related contexts. While the military necessity for dried plasma is well established, it will not be a central topic of discussion. Our goal is to foster dialogue primarily on topics that have not yet been thoroughly explored and on challenges that remain controversial or unresolved.

- 1. Address barriers to dried plasma implementation for pre-hospital use of dried plasma, such as: a) Reimbursement, b) Scope of practice for EMS care providers, and 3) Others
- 2. Are US blood centers and donor centers prepared to supply plasma for dried plasma production to support US EMS agencies and potential in-hospital use?
- 3. What is the regulatory outlook for dried plasma, for either in-hospital or out-of-hospital use? How is this different from the regulatory landscape for other (conventional) forms of plasma, such as FFP. Why?
- 4. What data are needed: 1) To support FDA approval (pre-hospital and in-hospital use)?; 2) For post-approval hemovigilance/monitoring (pre-hospital and in-hospital)?

- 5. What are the experience and lessons-learned from the clinical development of dried plasma products for FDA approval?
- 6. What are the opportunities for distribution of dried plasma products via pharmacy channels as compared to blood bank channels?
- 7. Does the growing use of whole blood and other transfusion approaches detract from the need for dried plasma?
- 8. Are additional authorizations for emergency use needed to enable organizations who need dried plasma? The US DoD can be supplied under an Emergency Use Authorization. Is there a way to enable civilian disaster preparedness/response at the national, state, and local levels?
- 9. What are potential in-hospital applications for dried plasma products?